Indication
Renal Transplant Recipient
4 clinical trials
4 products
Clinical trial
Early Substitution of Subcutaneous Abatacept for Belatacept as Costimulation Blockade to Minimize Calcineurin Inhibitors (CNI) Exposure After Kidney TransplantationStatus: Recruiting, Estimated PCD: 2024-12-01
Product
AbataceptClinical trial
Donor-derived Mesenchymal Stromal Cells, Alemtuzumab, Co-stimulation Blockade and Sirolimus for Tolerance Induction in Adult Kidney Allograft Recipients (ITN062ST)Status: Active (not recruiting), Estimated PCD: 2027-12-01
Clinical trial
A Phase III, Prospective, Open-Label, Randomized Clinical Trial Evaluating the Augmenting of Anti-SARS-CoV2 Immunity in Kidney Transplant Recipients Via a Heterologous Additional Dose With Janssen Ad26.CoV2.S VaccineStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Product
Janssen Ad26.CoV2.S VaccineClinical trial
Late Abatacept Conversion in Kidney Transplant Recipients Receiving Belatacept: a Prospective, Randomized Controlled Non-inferiority Trial. IM101-884Status: Recruiting, Estimated PCD: 2024-10-01
Product
Belatacept